logo-loader

Aegle Therapeutics Corp

Receive alerts
Market:
PRIVATE
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Aegle Therapeutics CEO Shelley Hartman joined Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The Phase 1/2a ready company isolating extracellular vesicles from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent scarring.